PRAME induces genomic instability in uveal melanoma.
Journal
Research square
Titre abrégé: Res Sq
Pays: United States
ID NLM: 101768035
Informations de publication
Date de publication:
26 Apr 2023
26 Apr 2023
Historique:
pubmed:
10
5
2023
medline:
10
5
2023
entrez:
10
5
2023
Statut:
epublish
Résumé
PRAME is a CUL2 ubiquitin ligase subunit that is normally expressed in the testis but becomes aberrantly overexpressed in many cancer types in association with aneuploidy and metastasis. Here, we show that PRAME is expressed predominantly in spermatogonia around the time of meiotic crossing-over in coordination with genes mediating DNA double strand break repair. Expression of PRAME in somatic cells upregulates pathways involved in meiosis, chromosome segregation and DNA repair, and it leads to increased DNA double strand breaks, telomere dysfunction and aneuploidy in neoplastic and non-neoplastic cells. This effect is mediated at least in part by ubiquitination of SMC1A and altered cohesin function. PRAME expression renders cells susceptible to inhibition of PARP1/2, suggesting increased dependence on alternative base excision repair pathways. These findings reveal a distinct oncogenic function of PRAME than can be targeted therapeutically in cancer.
Identifiants
pubmed: 37162820
doi: 10.21203/rs.3.rs-2861359/v1
pmc: PMC10168463
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : P30 CA240139
Pays : United States
Organisme : NEI NIH HHS
ID : P30 EY014801
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA125970
Pays : United States
Commentaires et corrections
Type : UpdateIn
Déclaration de conflit d'intérêts
Additional Declarations: Yes there is potential Competing Interest. Dr. Harbour is the inventor of intellectual property related to prognostic testing in uveal melanoma. He is a paid consultant for Castle Biosciences, licensee of this intellectual property, and he receives royalties from its commercialization. The work herein is not included in this intellectual property.